A Phase I/II Trial of Bortezomib, Low Dose Intravenous Melphalan and Dexamethasone for Patients with Relapsed Multiple Myeloma.

作者
Rakesh Popat,Catherine D. Williams,Mark A. Cook,Charles Craddock,Supratik Basu,Charles R.J. Singer,Liz Odeh,Nicola J. Foot,Heather E. Oakervee,James D. Cavenagh
出处
期刊:Blood [Elsevier BV]
卷期号:108 (11): 3542-3542 被引量:11
标识
DOI:10.1182/blood.v108.11.3542.3542
摘要

Abstract Background: Bortezomib is an effective treatment for patients with relapsed multiple myeloma with an overall response rate (MR+PR+CR) of 46% and time to progression of 6.2 months (APEX study). We and others have previously demonstrated potent in-vitro synergy with chemotherapeutic agents such as melphalan and it is likely that this will translate into improved responses in the clinical setting. Methods: This was a multi-centre, non-randomised Phase I/II clinical trial for patients with relapsed multiple myeloma. Bortezomib 1.3mg/m2 was given on Days 1,4,8 and 11 of a 28 day cycle, and intravenous melphalan on Day 2 for a maximum of 8 cycles. In the Phase I component melphalan was given at 2.5, 5,7.5 and 10mg/m2 in a dose escalation scheme and the maximum tolerated dose (MTD) of 7.5mg/m2 was taken forward to an expanded Phase II component. Dexamethasone 20mg on the day of and the day after each dose of bortezomib was permitted for progressive or stable disease after 2 or 4 cycles respectively. Responses were classified by EBMT criteria. Results: To date 39 patients have been enrolled (median age 61years [range 40–77]) with a median of 3 lines of prior therapy [range 1–5] of which 26 (67%) have had one previous autologous stem cell procedure and 4 (10%) have had two. 23 (59%) have had prior exposure to thalidomide and 4 (10%) to bortezomib. 36 have now completed at least 1 cycle and are therefore evaluable for response. The overall response rate (CR+PR+MR) across all treatment levels was 75% rising to 81% (CR 11%; nCR 3%; VGPR 8%; PR 39%; MR 19%) with the addition of dexamethasone in 13 cases for suboptimal response. Rapid responses were seen with the median time to response being 1 month [range 1–6]. The median time to progression is 10.1 months and the median overall survival has not yet been reached at a median follow-up of 7.4 months. Of the patients that have had disease progression 7 (35%) had responses of longer duration than their previous therapy. The MTD was defined by unacceptable delays in administering treatment due to myelosuppresion. The toxicities have been acceptable with 13 SAEs reported of which 8 were hospitalisation due to infection. The most common grade 3–4 adverse events were: thrombocytopenia (53%), infections (25%), neutropenia (17%) and neuropathy (17%). Three grade 3 cardiac events were seen (myocardial infarction, atrial fibrillation and cardiac failure) and GCSF was administered to 13 patients as treatment and prophylaxis of grade 4 neutropenia. 13 patients were withdrawn from the study due to toxicity of which 7 were for neuropathy and 3 for delayed haematological recovery. Of note, 11 patients (28%) had pre-existing grade 1 neuropathy prior to starting therapy. Summary: The combination of bortezomib, low dose intravenous melphalan and dexamethasone appears to be highly effective in patients with relapsed multiple myeloma where a response rate of 81% is seen with 14% achieving nCR/CR. The toxicity profile associated is predictable, manageable and predominantly haematological. Recruitment is ongoing to a total of 53 patients.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
大个的应助被科研通管家采纳,获得10
刚刚
Subwaid的应助被科研通管家采纳,获得10
1秒前
SciGPT的应助被wu采纳,获得10
1秒前
李健的应助被科研通管家采纳,获得10
1秒前
爆米花的应助被酷酷的时光采纳,获得10
1秒前
Lcx完成签到 ,获得积分10
1秒前
彭于晏的应助被科研通管家采纳,获得10
1秒前
沙拉完成签到,获得积分10
1秒前
1秒前
Maestro_S的应助被科研通管家采纳,获得10
1秒前
多情老十发布了新的文献求助10
1秒前
Zarc完成签到,获得积分10
1秒前
1秒前
1秒前
SYX发布了新的文献求助10
1秒前
bkagyin的应助被雨滴油纸伞采纳,获得10
1秒前
李爱国的应助被淡淡的冥茗采纳,获得10
1秒前
xu完成签到 ,获得积分20
1秒前
标致青雪发布了新的文献求助10
2秒前
2秒前
上官若男的应助被tomjeery采纳,获得10
2秒前
酷波er的应助被HuiLang采纳,获得10
2秒前
自觉柠檬发布了新的文献求助10
2秒前
lyn完成签到,获得积分10
2秒前
Laluna的应助被zzzzz采纳,获得10
3秒前
ren完成签到,获得积分10
3秒前
3秒前
丘比特的应助被星星海采纳,获得10
4秒前
4秒前
4秒前
hope完成签到 ,获得积分10
4秒前
斯文败类的应助被飞快的以山采纳,获得10
4秒前
年轻的牢登完成签到 ,获得积分10
5秒前
程汁发布了新的文献求助10
5秒前
5秒前
彭于彦祖的应助被xiaoyang采纳,获得30
5秒前
5秒前
小金今天自律了吗完成签到,获得积分10
5秒前
5秒前
诚心白羊完成签到,获得积分10
5秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180807
求助须知:如何正确求助?哪些是违规求助? 9570895
关于积分的说明 21815089
捐赠科研通 7777155
什么是DOI,文献DOI怎么找? 3433347
关于科研通互助平台的介绍 2557613
邀请新用户注册赠送积分活动 2479317